Personalised medicine in oncology: inequality aversion in a fast-moving field.

Microplastics and cancer: a looming threat?

Looking at cancer burden in Africa through a new lens.

Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial.

Balancing benefits, costs, and harms: policy implications of expanding cancer susceptibility testing from genetics clinics to the general population.

Cancer's new anxiety: not a death sentence, but delay.

Personalised medicine in oncology: inequality aversion in a fast-moving field.

Microplastics and cancer: a looming threat?

Looking at cancer burden in Africa through a new lens.

Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial.

Balancing benefits, costs, and harms: policy implications of expanding cancer susceptibility testing from genetics clinics to the general population.

Cancer's new anxiety: not a death sentence, but delay.